Cooley LLP announced today that it represented Trius Therapeutics in its acquisition by Cubist Pharmaceuticals. The total transaction is valued at up to $818 million.
Trius is a San Diego-based biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. Cubist is a bio-pharmaceutical company focused on the research, commercialization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.
The Cooley transaction team was led by partners Charles Bair and Barbara Borden, who heads the firm’s M&A practice, and included special counsel Rama Padmanabhan, and partners Thomas Welk (Compensation & Benefits) and Jackie Grise (Antitrust). Associates Wade Andrews, Holly Attiq, Daniel Gutierrez, Kevin Henderson, Justin Ho and Matt Robbins also provided critical support on the deal.
Cooley, which has been general outside corporate counsel to Trius since its inception in 2004, also advised the company on its 2010 initial public offering and on a series of subsequent financings.
View the Cubist press release here.
Related Posts:
- Cooley Represents Websense in its $1 Billion Acquisition by Vista Equity
- Cooley Advises Hot Topic in its $600 Million Sale to Sycamore Partners
- Cooley Advises Horizon Pharma on $660 Million Acquisition of Vidara Therapeutics
- Ambit Biosciences to be Acquired by Daiichi Sankyo for $410 Million
- Cooley Represents AcelRx Pharmaceuticals in Public Offering
